Literature DB >> 30936346

Waldenstrom-associated anti-MAG paraprotein polyneuropathy with neurogenic tremor.

Carlo Canepa1.   

Abstract

A 71-year-old female patient presented with a 14-year history of slowly progressive distal limb numbness, paraesthesia and reduced vibration perception, ataxic gait and intentional tremor. Examination revealed with a length-dependent sensory neuropathy. Nerve conduction studies showed a chronic sensorimotor inflammatory demyelinating polyneuropathy. Intravenous immunoglobulin treatment (on two occasions) proved ineffective. Serum electrophoresis showed increased monoclonal IgM with kappa light chains. Anti-myelin-associated glycoprotein (MAG) levels were extremely elevated, >70 000 BTU. Bone marrow biopsy revealed 15%-20% small B cells and positive MYD88 mutation, indicative of Waldenstrom macroglobulinaemia. A diagnosis of Waldenstrom-associated anti-MAG paraprotein neuropathy with intentional (neurogenic) tremor was made. Repeat nerve conduction study showed a severe sensory demyelinating neuropathy with no axonal lesion. Treatment with rituximab was given for 1 month with minimal improvement. Repeat anti-MAG levels dropped to 53 670 BTU, with minimal clinical improvement. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  neurology; peripheral nerve disease

Mesh:

Substances:

Year:  2019        PMID: 30936346      PMCID: PMC6453282          DOI: 10.1136/bcr-2018-228376

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  47 in total

1.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Authors:  Jean-Marc Léger; Karine Viala; Guillaume Nicolas; Alain Créange; Jean-Michel Vallat; Jean Pouget; Pierre Clavelou; Christophe Vial; Andreas Steck; Lucile Musset; Benoit Marin
Journal:  Neurology       Date:  2013-05-10       Impact factor: 9.910

Review 2.  Antibodies to glycoconjugates in neuropathy and motor neuron disease.

Authors:  N Latov
Journal:  Prog Brain Res       Date:  1994       Impact factor: 2.453

3.  Cancer risk in patients with monoclonal gammopathy of undetermined significance.

Authors:  H Gregersen; L Mellemkjaer; J Salling Ibsen; H T Sørensen; J H Olsen; J O Pedersen; J F Dahlerup
Journal:  Am J Hematol       Date:  2000-01       Impact factor: 10.047

4.  Paraproteins in the spinal fluid of patients with paraproteinemic polyneuropathies.

Authors:  M C Dalakas; N M Papadopoulos
Journal:  Ann Neurol       Date:  1984-06       Impact factor: 10.422

5.  Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy.

Authors:  E Nobile-Orazio; E Manfredini; M Carpo; N Meucci; S Monaco; S Ferrari; B Bonetti; G Cavaletti; F Gemignani; L Durelli
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

6.  Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1.

Authors:  R C McGarry; S L Helfand; R H Quarles; J C Roder
Journal:  Nature       Date:  1983 Nov 24-30       Impact factor: 49.962

7.  Tremor as a feature of chronic relapsing and dysgammaglobulinemic polyneuropathies. Incidence and management.

Authors:  M C Dalakas; H Teräväinen; W K Engel
Journal:  Arch Neurol       Date:  1984-07

8.  VIM thalamic stimulation for tremor in a patient with IgM paraproteinaemic demyelinating neuropathy.

Authors:  Evzen Růzicka; Robert Jech; Katerina Zárubová; Jan Roth; Dusan Urgosík
Journal:  Mov Disord       Date:  2003-10       Impact factor: 10.338

9.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

Authors:  Marinos C Dalakas; Goran Rakocevic; Mohammad Salajegheh; James M Dambrosia; Angelika F Hahn; Raghavan Raju; Beverly McElroy
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

10.  Cerebellar learning distinguishes inflammatory neuropathy with and without tremor.

Authors:  Petra Schwingenschuh; Tabish A Saifee; Petra Katschnig-Winter; Mary M Reilly; Michael P Lunn; Hadi Manji; Maria Aguirregomozcorta; Reinhold Schmidt; Kailash P Bhatia; John C Rothwell; Mark J Edwards
Journal:  Neurology       Date:  2013-04-17       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.